DOYLE WILLIAM F 4

What Happened
William F. Doyle, a director of ProKidney Corp. (PROK), was granted 135,000 derivative awards (stock options) on 2026-05-28. The filing reports an acquisition price of $0.00 (i.e., a grant/award), so no cash was paid by the insider at grant. This is an award under the issuer's non-employee director compensation policy and is routine compensation rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-05-28; Filing date: 2026-05-29 (timely file).
• Transaction type/code: A — Grant/Award (derivative securities). Reported price: $0.00.
• Amount: 135,000 options granted. Total dollar value not stated in filing.
• Vesting: Options vest in full on the earlier of the one‑year anniversary of the grant or the Company's next annual general shareholder meeting (per footnote).
• Source/plan: Granted under the issuer’s non‑employee director compensation policy (per footnote).
• Shares owned after transaction: Not specified in the provided filing details.

Context
These are option awards to a non‑employee director as part of standard director compensation. As a derivative grant, the options must vest (per schedule above) and then be exercised to convert into shares; there is no immediate sale or cash proceeds reported. Such awards are common for board members and do not by themselves indicate insider buying or selling sentiment.